Inhibitor Therapeutics, Inc. (INTI)
| Market Cap | 15.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.17M |
| Shares Out | 172.32M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,249 |
| Open | 0.1320 |
| Previous Close | 0.0890 |
| Day's Range | n/a |
| 52-Week Range | 0.0130 - 0.3000 |
| Beta | -0.81 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About INTI
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceut... [Read more]
Financial Performance
Financial StatementsNews
Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board
Scientific Advisory Board tasked with critical review of Phase 2b trial results to assess clinical usefulness prior to submission of New Drug Application ("NDA") to FDA TAMPA, Fla. , Dec. 19, 2023 /PR...
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
A critical milestone completed on the mission path of commercializing Itraconazole in numerous oncology indications. TAMPA, Fla.